|
Barbieri M, Paolisso G, Kimura M, Gardner JP, Boccardi V, Papa M, Hjelmborg JV, Christensen K, Brimacombe M, Nawrot TS, Staessen JA, Pollak MN, Aviv A. Higher circulating levels of igf-1 are associated with longer leukocyte telomere length in healthy subjects. Mech Ageing Dev 130: 771-6, 2009 |
|
|
Karp DD, Pollak MN, Cohen RB, Eisenberg PD, Haluska P, Yin D, Lipton A, Demers L, Leitzel K, Hixon ML, Terstappen LW, Garland L, Paz-Ares LG, Cardenal F, Langer CJ, Gualberto A. Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor Figitumumab (CP-751,871) in combination with Paclitaxel and Carboplatin. J Thorac Oncol?4:?1397-403,?2009. |
|
|
Gualberto A, Pollak M. Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. Curr Drug targets?10: 923-36,?2009. |
|
|
Beauchamp MC, Knafo A, Yasmeen A, carboni JM, Gottardis MM, Pollak MN, Gotlieb WH. BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide. Gynecol Oncol?115: 193-8,?2009. |
|
|
Pollak M. Macronutrient intake and cancer: how does dietary restriction influence tumor growth and why should we care? Cancer Prev Res(Phila Pa) 2: 698-701, 2009. |
|
|
Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 28: 3009-21, 2009. |
|
|
Su X, Colditz GA, Willett WC, Collins LC, Schnitt SJ, Connolly JL, Pollak MN, Rosner B, Tamimi RM. Genetic variation and circulating levels of IGF-I and IGFBP-3 in relation to risk of proliferative benign breast disease. Int J Cancer?126: 180-90,?2009. |
|
|
Dowling RJ, Pollak M, Sonenberg N. Current status and challenges associated with targeting mTOR for cancer therapy. BioDrugs 23: 77-91, 2009. |
|
|
Mavropoulos JC, Buschemeyer WC 3rd, Tewari AK, Fokhfeld D, Pollak M, Zhao Y, Febbo PG, Cohen P, Hwang D, Devi G, Demark-Wahnefried W, Westman EC, Peterson BL, PIzzo SV, Freedland SJ. The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model. Cancer Prev Res (Phila Pa) 2: 557-65, 2009. |
|
|
Rohrmann S, Sutcliffe CG, Bienstock JL, Monsegue D, Akereyeni F, Bradwin G, Rifai N, Pollak MN, Agurs-Collins T, Platz EA. Racial variation in sex steroid hormones and the insulin-like growth factor axis in umbilical cord blood of male neonates. Cancer Epidemiol Biomarkers Prev?18:1484-91, 2009. |
|
|
Pollak, M. Do cancer cells care if their host is hungry? Cell Metab 9: 401-3,?2009. |
|
|
Kaplan RC, Fitzpatrick AL, Pollak MN, Gardner JP, Jenny NS, McGinn AP, Kuller LH, Strickler HD, Kimura M, Psaty BM, Aviv A. Insulin-like growth factors and leukocyte telomere length: The cardiovascular health study. J Gerontol A Biol Sci Med Sci?64: 1103-6, 2009. |
|
|
Cox ME, Gleave ME, Zakikhani M, Bell RH, Piura E, Vickers E, Cunningham M, Larsson O, Fazli L, Pollak M. Insulin receptor expression by human prostate cancers. The Prostate 69: 33-40, 2009. |
|
|
Pollak, M. Aging, IGF-1, and diet. Aging Cell 8: 214,?2009. |
|
|
Avnet S, Sciacca L, Salerno M, Gancitano G, Cassarino MF, Longhi A, Zakikhani M, Carboni JM, Gottardis M, Giunti A, Pollak M, Vigneri R, Baldini N. Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res 69: 2443-52, 2009. |
|
|
Pollak M. Energy metabolism, cancer risk, and cancer prevention. Recent Results Cancer Res 181: 51-4, 2009. |
|
|
Sinotte M, Diorio C, Berube S, Pollak M, Brisson J. Genetic polymorphisms of the vitamin D binding protein and plasma concentrations of 25-hydroxyvitamin D in premenopausal women. Am J Clin Nutr 89: 634-40, 2009. |
|
|
Wolpin BM, Meyerhardt JA, Chan AT, Ng K, Chan JA, Wu K, Pollak MN, Giovannucci EL, Fuchs CS. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol 27: 176-85, 2009. |
|
|
Okereke OI, Selkoe DJ, Pollak MN, Stampfer MJ, Hu FB, Hankinson SE, Grodstein F. A profile of impaired insulin degradation in relation to late-life cognitive decline: A preliminary investigation. Int J Geriatr Psychiatry 24: 177-82, 2009.? |